Chat with us, powered by LiveChat

Proprotein Convertase Subtilisin/Kexin Type 9 Market (Product - SX-PCK9, K-312, LY3015014, and Others; Application - Cardiovascular Disease, Homozygous Familial Hypercholesterolaemia, Liver Disease, Metabolic Syndrome, and Others): Global Industry Analysis, Trends, Size, Share and Forecasts to 2030

Proprotein Convertase Subtilisin/Kexin Type 9 Market (Product - SX-PCK9, K-312, LY3015014, and Others; Application - Cardiovascular Disease, Homozygous Familial Hypercholesterolaemia, Liver Disease, Metabolic Syndrome, and Others): Global Industry Analysis, Trends, Size, Share and Forecasts to 2030

Report Code: IGR0405 Category: Healthcare & Medical Devices Published: November, 2023

A recent report published by Infinium Global Research on proprotein convertase subtilisin/kexin type 9 market provides in-depth analysis of segments and sub-segments in the global as well as regional proprotein convertase subtilisin/kexin type 9 market. The study also highlights the impact of drivers, restraints, and macro indicators on the global and regional proprotein convertase subtilisin/kexin type 9 market over the short term as well as long term. The report is a comprehensive presentation of trends, forecast and dollar values of global proprotein convertase subtilisin/kexin type 9 market.

Market Insight:

The global proprotein convertase subtilisin/kexin type 9 market was valued at USD 2.46 billion in 2022 and is expected to reach USD 5.09 billion in 2030, with a CAGR of 9.56% during the forecast period 2023-2030.

The proprotein convertase subtilisin/Kexin type 9 market is associated with drugs targeting PCSK9, a protein that plays a crucial role in regulating cholesterol levels in the human body. This market revolves around medications developed to manage high cholesterol, particularly for individuals who either do not respond well to traditional cholesterol-lowering drugs or require additional therapy to maintain healthy cholesterol levels. These PCSK9 inhibitors work by reducing Low-density Lipoprotein (LDL) cholesterol, often referred to as "bad" cholesterol, hence diminishing the risk of cardiovascular diseases.

The proprotein convertase subtilisin/kexin type 9 (PCSK9) market is driven by rising cardiovascular disease concerns. Cardiovascular diseases remain a leading cause of mortality worldwide, and reducing LDL cholesterol is a crucial factor in managing cardiovascular risk. Given the robust impact of PCSK9 inhibitors in significantly lowering LDL cholesterol, these drugs are increasingly sought after as a critical component of cardiovascular risk management strategies, thus driving their market growth. Moreover, the clinical effectiveness and high efficacy of these inhibitors fuel the market growth. The exceptional clinical effectiveness and high efficacy of these inhibitors in managing high cholesterol levels. PCSK9 inhibitors have demonstrated remarkable efficacy in reducing LDL cholesterol levels, especially in patients who are unable to achieve their target cholesterol levels through conventional therapies like statins. Their ability to significantly lower LDL cholesterol contributes to their appeal among healthcare professionals and patients, driving demand for these drugs. However, high cost and accessibility factors can act as a barrier to market growth. Furthermore, the evolving research landscape and ongoing clinical trials present an opportunity for PCSK9 inhibitors to potentially receive expanded indications, catering to a wider range of cardiovascular conditions or facilitating combination therapies for comprehensive heart health management. This potential expansion stands as a valuable opportunity to notably enhance the market potential of PCSK9 inhibitors.

Proprotein Convertase Subtilisin/Kexin Type 9 Market |IGR

North America is expected to hold the most prominent market share in the upcoming forecast period due to the high prevalence of cardiovascular diseases and atherosclerosis, supported by sophisticated healthcare infrastructure and significant advancements by key market players. Furthermore, the increasing research and development approvals contribute to the region's continued dominance in the coming years. On the other hand, the Asia Pacific region is projected to showcase the most substantial growth in the global market for proprotein convertase subtilisin/kexin type 9 during the forecast period. This growth trajectory is driven by escalating demand for healthy food products within emerging markets. Countries with rapid development in this region are enhancing their healthcare infrastructure and raising awareness regarding the treatment of heart diseases. Additionally, the rise in the elderly population facing heart-related issues due to sedentary lifestyles is expected to further drive market growth in the region.

Report Scope of the Proprotein Convertase Subtilisin/Kexin Type 9 Market:

Report Coverage Details
Market Size in 2022 USD 2.46 Billion
Market Size by 2030 USD 5.09 Billion
Growth Rate from 2023 to 2030 CAGR of 9.56%
Largest Market North America
No. of Pages 180
Market Drivers
  • The proprotein convertase subtilisin/kexin type 9 market is driven by rising cardiovascular disease concerns.

  • The clinical effectiveness and high efficacy of proprotein convertase subtilisin/kexin type 9 fuels the market growth.

Market Segmentation By Product, and By Application
Regional Scope North America, Europe, Asia Pacific, and RoW

Segment Covered

The report on global proprotein convertase subtilisin/kexin type 9 market covers segments such as product, and application. On the basis of product, the sub-markets include SX-PCK9, K-312, LY3015014, and others. On the basis of application, the sub-markets include cardiovascular disease, homozygous familial hypercholesterolaemia, liver disease, metabolic syndrome, and others.

Companies Profiled:

The report provides profiles of the companies in the market such as Amgen Inc., Novartis AG, Eli Lilly and Company, Ensemble Therapeutics Corporation, Alnylam Pharmaceuticals, Inc., Regeneron Pharmaceuticals Inc., AFFiRiS AG, Merck & Co., Inc., Sanofi, and AstraZeneca.

Report Highlights:

The report provides deep insights into demand forecasts, market trends, and micro and macro indicators. In addition, this report provides insights into the factors that are driving and restraining the growth in this market. Moreover, The IGR-Growth Matrix analysis given in the report brings an insight into the investment areas that existing or new market players can consider. The report provides insights into the market using analytical tools such as Porter's five forces analysis and DRO analysis of the proprotein convertase subtilisin/kexin type 9 market. Moreover, the study highlights current market trends and provides forecasts from 2023-2030. We also have highlighted future trends in the market that will affect the demand during the forecast period. Moreover, the competitive analysis given in each regional market brings an insight into the market share of the leading players.


Frequently Asked Questions (FAQ's)

The global proprotein convertase subtilisin/kexin type 9 market was valued at USD 2.46 Billion in 2022.
It is likely to grow at a CAGR of 9.56% during the forecast period 2023-2030.
The global proprotein convertase subtilisin/kexin type 9 market is estimated to reach USD 5.09 Billion by the end of 2030.
North America is anticipated to exhibit high demand for proprotein convertase subtilisin/kexin type 9 market during the forecast period.
Amgen Inc., Novartis AG, Eli Lilly and Company, Ensemble Therapeutics Corporation, Alnylam Pharmaceuticals, Inc., Regeneron Pharmaceuticals Inc., AFFiRiS AG, Merck & Co., Inc., Sanofi, and AstraZeneca.
CHOOSE LICENCE TYPE

Please Choose One of them.

Google translate
© 2024. Infinium Global Research LLP. All Rights Reserved.